Mrl Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.56 Cr
as on 20-12-2024
- Satisfied Charges ₹ 6.00 M
as on 20-12-2024
- Revenue %
(FY 2021)
- Profit 476.72%
(FY 2021)
- Ebitda 622.99%
(FY 2021)
- Net Worth 72.83%
(FY 2021)
- Total Assets 8330.44%
(FY 2021)
About Mrl Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.56 Cr. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ahsan Ahmad and Shobhit Tyagi serve as directors at the Company.
- CIN/LLPIN
U51909DL2020PTC362594
- Company No.
362594
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2020
- Date of AGM
-
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mrl Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ahsan Ahmad  | Director | 01-Apr-2022 | Current |
| Shobhit Tyagi | Director | 01-Apr-2022 | Current |
Financial Performance of Mrl Pharma.
Mrl Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 476.72% increase in profit. The company's net worth Soared by an impressive increase of 72.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mrl Pharma?
In 2021, Mrl Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Msp Healthcare Private LimitedActive 2 years 4 monthsAhsan Ahmad and Shobhit Tyagi are mutual person
- Drashika Health And Seva FoundationActive 2 years 3 months
Ahsan Ahmad and Shobhit Tyagi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 14 Jun 2024 | ₹1.00 Cr | Open |
Others Creation Date: 29 Jan 2024 | ₹5.62 M | Open |
Hdfc Bank Limited Creation Date: 27 Jul 2022 | ₹6.00 M | Satisfied |
How Many Employees Work at Mrl Pharma?
Unlock and access historical data on people associated with Mrl Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mrl Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mrl Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
